FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137052596> ?p ?o ?g. }

• W3137052596 endingPage "372" @default.
• W3137052596 startingPage "362" @default.
• W3137052596 abstract "Background The European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) investigates the natural history of Friedreich's ataxia. We aimed to assess progression characteristics and to identify patient groups with differential progression rates based on longitudinal 4-year data to inform upcoming clinical trials in Friedreich's ataxia. Methods EFACTS is a prospective, observational cohort study based on an ongoing and open-ended registry. Patients with genetically confirmed Friedreich's ataxia were seen annually at 11 clinical centres in seven European countries (Austria, Belgium, France, Germany, Italy, Spain, and the UK). Data from baseline to 4-year follow-up were included in the current analysis. Our primary endpoints were the Scale for the Assessment and Rating of Ataxia (SARA) and the activities of daily living (ADL). Linear mixed-effect models were used to analyse annual disease progression for the entire cohort and subgroups defined by age of onset and ambulatory abilities. Power calculations were done for potential trial designs. This study is registered with ClinicalTrials.gov, NCT02069509. Findings Between Sept 15, 2010, and Nov 20, 2018, of 914 individuals assessed for eligibility, 602 patients were included. Of these, 552 (92%) patients contributed data with at least one follow-up visit. Annual progression rate for SARA was 0·82 points (SE 0·05) in the overall cohort, and higher in patients who were ambulatory (1·12 [0·07]) than non-ambulatory (0·50 [0·07]). ADL worsened by 0·93 (SE 0·05) points per year in the entire cohort, with similar progression rates in patients who were ambulatory (0·94 [0·07]) and non-ambulatory (0·91 [0·08]). Although both SARA and ADL showed slightly greater worsening in patients with typical onset (symptom onset at ≤24 years) than those with late onset (symptom onset ≥25 years), differences in progression slopes were not significant. For a 2-year parallel-group trial, 230 (115 per group) patients would be required to detect a 50% reduction in SARA progression at 80% power: 118 (59 per group) if only individuals who are ambulatory are included. With ADL as the primary outcome, 190 (95 per group) patients with Friedreich's ataxia would be needed, and fewer patients would be required if only individuals with early-onset are included. Interpretation Our findings for stage-dependent progression rates have important implications for clinicians and researchers, as they provide reliable outcome measures to monitor disease progression, and enable tailored sample size calculation to guide upcoming clinical trial designs in Friedreich's ataxia. Funding European Commission, Voyager Therapeutics, and EuroAtaxia. The European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) investigates the natural history of Friedreich's ataxia. We aimed to assess progression characteristics and to identify patient groups with differential progression rates based on longitudinal 4-year data to inform upcoming clinical trials in Friedreich's ataxia. EFACTS is a prospective, observational cohort study based on an ongoing and open-ended registry. Patients with genetically confirmed Friedreich's ataxia were seen annually at 11 clinical centres in seven European countries (Austria, Belgium, France, Germany, Italy, Spain, and the UK). Data from baseline to 4-year follow-up were included in the current analysis. Our primary endpoints were the Scale for the Assessment and Rating of Ataxia (SARA) and the activities of daily living (ADL). Linear mixed-effect models were used to analyse annual disease progression for the entire cohort and subgroups defined by age of onset and ambulatory abilities. Power calculations were done for potential trial designs. This study is registered with ClinicalTrials.gov, NCT02069509. Between Sept 15, 2010, and Nov 20, 2018, of 914 individuals assessed for eligibility, 602 patients were included. Of these, 552 (92%) patients contributed data with at least one follow-up visit. Annual progression rate for SARA was 0·82 points (SE 0·05) in the overall cohort, and higher in patients who were ambulatory (1·12 [0·07]) than non-ambulatory (0·50 [0·07]). ADL worsened by 0·93 (SE 0·05) points per year in the entire cohort, with similar progression rates in patients who were ambulatory (0·94 [0·07]) and non-ambulatory (0·91 [0·08]). Although both SARA and ADL showed slightly greater worsening in patients with typical onset (symptom onset at ≤24 years) than those with late onset (symptom onset ≥25 years), differences in progression slopes were not significant. For a 2-year parallel-group trial, 230 (115 per group) patients would be required to detect a 50% reduction in SARA progression at 80% power: 118 (59 per group) if only individuals who are ambulatory are included. With ADL as the primary outcome, 190 (95 per group) patients with Friedreich's ataxia would be needed, and fewer patients would be required if only individuals with early-onset are included. Our findings for stage-dependent progression rates have important implications for clinicians and researchers, as they provide reliable outcome measures to monitor disease progression, and enable tailored sample size calculation to guide upcoming clinical trial designs in Friedreich's ataxia." @default.
• W3137052596 created "2021-03-29" @default.
• W3137052596 creator A5000608187 @default.
• W3137052596 creator A5002298880 @default.
• W3137052596 creator A5005438826 @default.
• W3137052596 creator A5009226354 @default.
• W3137052596 creator A5011213885 @default.
• W3137052596 creator A5011890829 @default.
• W3137052596 creator A5012241488 @default.
• W3137052596 creator A5013428782 @default.
• W3137052596 creator A5014302098 @default.
• W3137052596 creator A5015259932 @default.
• W3137052596 creator A5016210367 @default.
• W3137052596 creator A5020107828 @default.
• W3137052596 creator A5024040961 @default.
• W3137052596 creator A5024252409 @default.
• W3137052596 creator A5026565602 @default.
• W3137052596 creator A5027293126 @default.
• W3137052596 creator A5029839211 @default.
• W3137052596 creator A5036644008 @default.
• W3137052596 creator A5036929784 @default.
• W3137052596 creator A5037328125 @default.
• W3137052596 creator A5039235207 @default.
• W3137052596 creator A5039729410 @default.
• W3137052596 creator A5040386348 @default.
• W3137052596 creator A5044521657 @default.
• W3137052596 creator A5047376869 @default.
• W3137052596 creator A5047819566 @default.
• W3137052596 creator A5049569315 @default.
• W3137052596 creator A5050537915 @default.
• W3137052596 creator A5052216851 @default.
• W3137052596 creator A5056363092 @default.
• W3137052596 creator A5057192241 @default.
• W3137052596 creator A5058514008 @default.
• W3137052596 creator A5060699960 @default.
• W3137052596 creator A5063319800 @default.
• W3137052596 creator A5072221005 @default.
• W3137052596 creator A5073735143 @default.
• W3137052596 creator A5076004371 @default.
• W3137052596 creator A5078587237 @default.
• W3137052596 creator A5080418392 @default.
• W3137052596 creator A5081473300 @default.
• W3137052596 creator A5083167091 @default.
• W3137052596 creator A5084067197 @default.
• W3137052596 creator A5086356522 @default.
• W3137052596 creator A5087469218 @default.
• W3137052596 creator A5088943659 @default.
• W3137052596 creator A5089487905 @default.
• W3137052596 creator A5090357582 @default.
• W3137052596 date "2021-05-01" @default.
• W3137052596 modified "2023-10-17" @default.
• W3137052596 title "Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study" @default.
• W3137052596 cites W2030422836 @default.
• W3137052596 cites W2043288745 @default.
• W3137052596 cites W2047905051 @default.
• W3137052596 cites W2072093241 @default.
• W3137052596 cites W2091967505 @default.
• W3137052596 cites W2095184629 @default.
• W3137052596 cites W2095560475 @default.
• W3137052596 cites W2102236934 @default.
• W3137052596 cites W2117257456 @default.
• W3137052596 cites W2126278820 @default.
• W3137052596 cites W2134435694 @default.
• W3137052596 cites W2136707529 @default.
• W3137052596 cites W2154795762 @default.
• W3137052596 cites W2155026242 @default.
• W3137052596 cites W2158155007 @default.
• W3137052596 cites W2167527362 @default.
• W3137052596 cites W2336904126 @default.
• W3137052596 cites W2473786944 @default.
• W3137052596 cites W2480685735 @default.
• W3137052596 cites W2552065052 @default.
• W3137052596 cites W2724353996 @default.
• W3137052596 cites W2765285950 @default.
• W3137052596 cites W2810078876 @default.
• W3137052596 cites W2885865777 @default.
• W3137052596 cites W2969405288 @default.
• W3137052596 cites W2982337851 @default.
• W3137052596 cites W3000395429 @default.
• W3137052596 cites W3011998015 @default.
• W3137052596 doi "https://doi.org/10.1016/s1474-4422(21)00027-2" @default.
• W3137052596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33770527" @default.
• W3137052596 hasPublicationYear "2021" @default.
• W3137052596 type Work @default.
• W3137052596 sameAs 3137052596 @default.
• W3137052596 citedByCount "44" @default.
• W3137052596 countsByYear W31370525962021 @default.
• W3137052596 countsByYear W31370525962022 @default.
• W3137052596 countsByYear W31370525962023 @default.
• W3137052596 crossrefType "journal-article" @default.
• W3137052596 hasAuthorship W3137052596A5000608187 @default.
• W3137052596 hasAuthorship W3137052596A5002298880 @default.
• W3137052596 hasAuthorship W3137052596A5005438826 @default.
• W3137052596 hasAuthorship W3137052596A5009226354 @default.
• W3137052596 hasAuthorship W3137052596A5011213885 @default.
• W3137052596 hasAuthorship W3137052596A5011890829 @default.
• W3137052596 hasAuthorship W3137052596A5012241488 @default.
• W3137052596 hasAuthorship W3137052596A5013428782 @default.

• next